In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...

Research has shown that patients who share race and ethnicity with their medical providers have better outcomes, but often ...

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus ...

GSK's BCMA-directed antibody-drug conjugate Blenrep reduced the risk of death by 42 ... or refractory multiple myeloma." The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex ...

The city of Fayetteville has introduced "The One Test," which offers a more immediate assessment of a firefighter's risk of ...

With Iowa maintaining the second-highest rate and fastest-growing rate of new cancers nationally, advancements in treatment ...

With Iowa maintaining the second-highest and fastest-growing rate of new cancers nationally, according to a 2025 Cancer in ...

Arizona is similarly at risk for measles because the state has several pockets of extremely low vaccination rates, including ...

Produced by the Iowa Cancer Registry, the annual cancer report collects data on all Iowa residents diagnosed with cancer.

The Iowa Cancer Registry released the 2025 Cancer in Iowa report Tuesday, focused on the changing metrics of cancer ...

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma market. A couple of months ...